Neuphoria Therapeutics Inc. NEUP

3.65 0.00 0.00% as of 25 Sep
Market cap
$19.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17
P/E ratio
0.00 0.00 — 0.00 0.00 — 0.00 0.00 0.00 0.00
P/S ratio
1.23 0.74 — 574.69 1,463.61 — 558.54 558.54 558.54 558.54
P/FCF ratio
0.00 50.41 — 0.00 0.00 — 0.00 0.00 0.00 0.00
P/Operating CF
15.83 (3.21) — (14.99) (39.96) — (135.99) (135.99) (135.99) (135.99)
P/B ratio
0.78 0.61 — 0.00 15.27 — 21.54 21.54 21.54 21.54
EV/Sales
0.02 (0.12) — 543.36 1,408.25 — 543.25 543.25 543.25 543.25
EV/EBITDA
0.00 3.98 — 0.00 0.00 — 0.00 0.00 0.00 0.00
EV/FCF
(0.02) (8.12) — (4.49) (19.13) — (80.32) (80.32) (80.32) (80.32)
Current Ratio
27.85 3.56 3.45 4.87 12.46 13.10 1.01 1.82 2.70 3.92
Net Debt/EBITDA
1.26 30.65 0.73 0.56 1.59 4.92 (0.80) (0.21) 0.15 2.02
Debt/Equity
0.00 0.00 0.00 0.01 0.01 0.01 0.96 1.11 1.26 0.46
ROE
(61.70%) (2.03%) (78.44%) (67.56%) (41.08%) (29.37%) (48.22%) (60.13%) (85.08%) (23.77%)
ROA
(46.95%) (1.31%) (55.12%) (56.31%) (35.91%) (20.26%) (15.95%) (16.91%) (77.11%) (9.20%)
ROIC
(217.17%) (14.97%) (229.05%) (135.35%) (57.33%) (24.03%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(66.23%) (3.42%) (165.40%) (201.90%) (56.58%) (30.44%) (637.95%) (74.88%) (98.84%) (15.62%)
Average Days of Receivables
252.85 0.28 0.00 10,508.55 9,390.97 0.00 23,295.91 4,539.58 874.84 195.77
Earnings Yield
(115.33%) (15.34%) — (0.10%) (0.03%) — (0.01%) (0.01%) (0.01%) (0.01%)
Free Cash Flow Yield
(63.52%) 1.98% — (21.06%) (5.03%) — (1.21%) (1.21%) (1.21%) (1.21%)
Free Cash Flow per Share
(2.81) 0.05 (17.64) (21.54) (25.00) (15.54) (0.76) (3.22) (4.79) (0.06)
Book value per Share
5.60 11.71 21.02 32.38 65.93 98.55 2.50 3.47 4.08 9.81
Free Cash Flow
(12.35) 0.08 (14.68) (14.64) (15.66) (5.61) (2.63) (10.70) (14.73) (0.18)
EV/EBIT
0.00 1.64 — 0.00 0.00 — 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 23 Sep 2026